Christopher J. Sweeney
Massachusetts Eye and Ear Infirmary(US)Royal Adelaide Hospital(AU)Harvard University(US)Australian Institute of Business(AU)Dana-Farber Cancer Institute(US)Centre for Cancer Biology(AU)Centre for Cancer Biology(AU)Australian and New Zealand Urogenital and Prostate Cancer Trials Group(AU)The University of Adelaide(AU)University of Adelaide(AU)Syngenta (Switzerland)(CH)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications, Cancer, Lipids, and Metabolism, Cancer Genomics and Diagnostics
Most-Cited Works
- → Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer(2015)2,781 cited
- → Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer(2019)1,552 cited
- → Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial(2018)1,083 cited
- → Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017(2017)639 cited
- → Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study(2019)548 cited
- → Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study(2018)